A pharmaceutical formulation for topical dental administration or medical (e.g., implant) treatment, including effective amounts of: at least one antimicrobial compound; at least one peroxide source compound; and at least one gel agent. Also disclosed are methods of oral anatomy treatment. The pharmaceutical formulation and treatment methods provide the patient with oral anatomy benefits including, for example, decreased or arrested gum recession; decreased or arrested bone recession; decreased or arrested bone mass loss; decreased or eliminated pain; decreased or eliminated bleeding; decreased or eliminated swelling; enhanced regeneration of bone; enhanced soft tissue repair; or a combination thereof.

A pharmaceutical formulation for topical dental administration or medical (e.g., implant) treatment, including effective amounts of: at least one antimicrobial compound; at least one peroxide source compound; and at least one gel agent. Also disclosed are methods of oral anatomy treatment. The pharmaceutical formulation and treatment methods provide the patient with oral anatomy benefits including, for example, decreased or arrested gum recession; decreased or arrested bone recession; decreased or arrested bone mass loss; decreased or eliminated pain; decreased or eliminated bleeding; decreased or eliminated swelling; enhanced regeneration of bone; enhanced soft tissue repair; or a combination thereof.

Described herein are compositions and methods for treating hyperkeratosis disorders such as dandruff, psoriasis, acne vulgaris, warts, corns, calluses, palmoplantar keratodermas, ichthyosis, seborrheic dermatitis, meibomian gland dysfunction, HPV infection, lichen planus, aclinic keratosis, seborrheic keratosis, etc. Said compositions comprise a selenium-containing amino acid as keratolytic agent, and are topically administered to the skin or eyelid margin of the patient. In some embodiments, the composition comprises a selenium-containing amino acid such as selenium methionine or selenium cysteine formulated in a ophthalmic, dermatological, or cosmetic dosage form.

Described herein are compositions and methods for treating hyperkeratosis disorders such as dandruff, psoriasis, acne vulgaris, warts, corns, calluses, palmoplantar keratodermas, ichthyosis, seborrheic dermatitis, meibomian gland dysfunction, HPV infection, lichen planus, aclinic keratosis, seborrheic keratosis, etc. Said compositions comprise a selenium-containing amino acid as keratolytic agent, and are topically administered to the skin or eyelid margin of the patient. In some embodiments, the composition comprises a selenium-containing amino acid such as selenium methionine or selenium cysteine formulated in a ophthalmic, dermatological, or cosmetic dosage form.

Described herein are compositions and methods for the treatment of meibomian gland dysfunction. Said compositions and methods comprise keratolytic agents, such as salicylic acid, selenium disulfide, or the like. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from meibomian gland dysfunction.

Described herein are compositions and methods for the treatment of meibomian gland dysfunction. Said compositions and methods comprise keratolytic agents, such as salicylic acid, selenium disulfide, or the like. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from meibomian gland dysfunction.

A method of treating or preventing P. acnes and/or S. aureus infection is described, involving contacting P. acnes and/or S. aureus, or a physiological locus infected or susceptible to infection by P. acnes and/or S. aureus, with at least one of specified bacteriolytic agents. Corresponding pharmaceutical compositions containing such bacteriolytic agents are described, which are useful for treatment or prophylaxis of acne vulgaris and/or S. aureus infection, including methicillin-resistant S. aureus infection.

A method of treating or preventing P. acnes and/or S. aureus infection is described, involving contacting P. acnes and/or S. aureus, or a physiological locus infected or susceptible to infection by P. acnes and/or S. aureus, with at least one of specified bacteriolytic agents. Corresponding pharmaceutical compositions containing such bacteriolytic agents are described, which are useful for treatment or prophylaxis of acne vulgaris and/or S. aureus infection, including methicillin-resistant S. aureus infection.

The present invention relates to a new multifunctional debridement and/or antifouling composition comprising H.sub.2O.sub.2 at a final concentration of between 0.1-5% v/v, and a composite hydrogel formulation comprising pluronic acid at a concentration of 10-40% w/v, wherein the composition is in liquid form at room temperature. The composition disclosed herein is antimicrobial and/or anti-inflammatory and is particular useful in periimplantitis treatment and implant health maintenance, in periodontitis and periodontal health and in wound care and chronic ulcer care.

In some aspects, the techniques described herein relate to a topical dermatologic acne treatment method using a cream. The treatment method uses two steps, first providing a bactericidal component and second providing a skin revitalizing complex. The bactericidal component clears the acne causing bacteria. The subsequent skin revitalizing complex revitalizes and conditions the skin and aids in return of natural skin flora and microbiome to prevent subsequent outbreaks. The skin revitalizing complex can include a variety of components such as: niacinamide, retinol, bakuchiol, green coffee bean extract, green tea extract, epilobium fleischeri extract, citric acid, dimethicone, and pentaerythrityl tetracaprylate. The skin revitalizing complex restores natural elasticity and oil production of the skin, decrease sebum production, and provide necessary conditioning of the skin to provide for the natural skin flora and microbiome to repopulate and flourish on a surface of the skin.